Genentech Inc. has no fusion proteins in clinical development, but its technology for producing such proteins began to bear fruit last week, yielding GNE a piece of Immunex Corp.'s revenues from its Enbrel p75TNFR:Fc fusion protein in rheumatoid arthritis. GNE plans to license the patent co-exclusively for specific fusion proteins, reserving the right to develop any antibody-receptor fusion protein it chooses.

GNE's U.S. Patents include Nos. 5,116,964; 5,428,130; 5,455,165 and 5,514,582, and patent applications are pending in other